Fortress Biotech, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Asset Purchase Agreements (Narrative) (Details)

Asset Purchase Agreements (Narrative) (Details) $ in Thousands					3 Months Ended	9 Months Ended
	Jul. 15, 2024 USD ($) director	Jun. 27, 2024 USD ($) D	May 13, 2024	Jul. 28, 2023 USD ($)	Sep. 30, 2024 USD ($)	Sep. 30, 2024 USD ($)	Dec. 31, 2023 USD ($)
Number of days to dispose of assets purchased			180 days
Purchase Price recorded in accrued expenses - other					$ 3,123	$ 3,123	$ 817
Crystalys Therapeutics, Inc
Capitalization in equity securities	$ 150,000
Avenue \| InvaGen
Contingent fee payable from proceeds of future financing					$ 4,000	4,000
Payments of milestones						$ 700
Percentage of contingent fee payable					7.50%	7.50%
Mustang \| UBriGene
Consideration Transferred		$ 1,400
Consideration Transferred		$ 4,700		$ 6,000
Gain on sale of asset				1,400
Transaction Related Expenses				$ 300
Interest rate on outstanding liability		5.00%
Upfront payment		$ 100
Upfront payment due period \| D		5
Subsequent amount		$ 1,300
Subsequent payment due period		12 months
Purchase Price recorded in accrued expenses - other		$ 1,300			$ 1,300	$ 1,300
Fair value of assets less cost to sell in repurchase transaction		2,200
Remaining purchase consideration allocated to the supplies repurchased		2,500
Fair value of supplies with no alternative future use expensed as research and development expense		2,200
Fair Value of Supplies With Alternative Future Use Expensed as Research and Development Expense		300
Aggregate value of assets and associated supplies met the criteria to be classified as held for sale at the date of acquisition		2,200
Outstanding receivable from uBriGene		6,900
Outstanding payables of the company		3,600
Net Receivable from uBriGene		$ 3,300
Urica
Percentage of equity to be held	35.00%
Urica \| Crystalys Therapeutics, Inc
Urica's equity position	15.00%
Percentage of royalty on future net sales	3.00%
Reimbursement of Research and Development	$ 600
Number of directors \| director	1
Maximum repurchase amount of assets sold under agreements	$ 6,400
Liability	600
Recorded accretion					300
Urica \| Crystalys Therapeutics, Inc \| Minimum
Amount of minimum qualified financing required	$ 120,000
Net Assets Below 20 Million \| Mustang \| UBriGene
Asset acquisition consideration, threshold net assets considered for delay in subsequent payment					$ 20,000	$ 20,000
Subsequent payment extended due period		6 months